Yes, small intestinal bacterial overgrowth (SIBO) is a real, recognized condition. The American College of Gastroenterology (ACG) defines it as the presence of excessive numbers of bacteria in the small bowel causing gastrointestinal symptoms (Pimentel 2020). What gastroenterologists actually argue about is narrower and more interesting: how to measure it, how often it explains the bloating of ordinary IBS, and how much to trust the breath test that most diagnoses now rest on.
If a doctor has told you SIBO "is not real", that sentence probably contained less than it sounded like. This article separates the parts that are settled from the parts that are contested, using the guidelines themselves rather than anyone's opinion of them, and ends with a script for the appointment. It is not a way to diagnose yourself, and it does not recommend starting or stopping any medicine.
Is SIBO a real condition, or a made-up diagnosis?
SIBO is real in the sense that matters medically: bacteria in the small intestine can multiply beyond normal limits and cause symptoms and nutrient loss. It was described more than a century ago as a consequence of blind loops and strictures (Kashyap 2024). What was added later, and remains unproven, is the claim that it explains a large share of common functional bloating. Two related questions come up often: can SSRIs or propranolol affect SIBO? and can SIBO cause burning red hands after eating?. A common puzzle is relief while away; see why do SIBO symptoms disappear on vacation?. On why SIBO keeps coming back, see how to improve motility with SIBO.
The history matters because it explains why two sensible doctors can both be telling the truth. In the original, classical picture, the "blind loop syndrome", surgery, strictures or diseases such as scleroderma left a segment of small bowel stagnant. Bacteria overgrew, bile acids were disrupted, and people developed diarrhea, fatty stools and deficiencies of vitamin B12 and fat-soluble vitamins. Diagnosis rested on a compatible history, bacterial counts in a jejunal aspirate and a response to antibiotics. Almost nobody disputes that this is a genuine disease.
Then, about two decades ago, a second idea arrived. The lactulose breath test, originally developed to measure how fast food moves from mouth to caecum, began to be used to diagnose overgrowth in people whose only complaint was bloating, gas and altered bowel habit. The hypothesis was that a hidden overgrowth might sit behind many cases of IBS. A 2024 clinical practice update endorsed by the European and American neurogastroenterology societies, states plainly that "after two decades, this hypothesis remains unproven" (Kashyap 2024). That is the real source of the "SIBO is not real" shorthand. It is a criticism of the second idea, not the first. If your own test came back negative, see negative SIBO breath test but still symptoms.
The 2020 AGA practice update says something compatible from a more neutral position. It states that the definition of SIBO "lacks precision and consistency", that its true prevalence is undefined, and that a major impediment is our limited understanding of what a normal small intestinal microbial population looks like (Quigley 2020). Both papers agree the term is real and used loosely. They disagree about how loosely.
Reddit shows the lived version of this gap. In two threads in r/SIBO, one where a poster was told by a primary care doctor (GP in the UK) that SIBO is not a real condition (thread) and one where a physician reportedly said it does not exist (thread), the replies run from anger to practical advice. People describe being dismissed for years, being sent from primary care to gastroenterologist to ER, and sometimes turning to naturopaths. Some replies say SIBO was only "discovered" in the last decade or that doctors are never taught it. Neither is accurate: the classical syndrome has been described for over a century. What is new is the application to common symptoms, and that is exactly the part that remains contested.
What does the ACG guideline say about SIBO?
The 2020 ACG guideline defines SIBO as a clinical syndrome of GI symptoms caused by excessive small bowel bacteria, makes six graded recommendations that are all "conditional", and rates the evidence behind them as "very low" or "low". Its authors acknowledge that current breath tests have low sensitivity and specificity.
It is worth reading what it actually says, because both fans and critics tend to summarize it from memory. The guideline's own summary table contains these graded recommendations (Pimentel 2020):
| Topic | ACG statement (paraphrased) | Strength and evidence |
|---|---|---|
| IBS | Suggests breath testing (glucose or lactulose) for diagnosis in patients with IBS | Conditional, very low |
| Motility disorders | Suggests breath testing in symptomatic patients with suspected motility disorders | Conditional, very low |
| Prior surgery | Suggests testing in symptomatic patients (pain, gas, bloating, diarrhea) with previous luminal abdominal surgery | Conditional, very low |
| PPIs | Suggests against breath testing in asymptomatic patients on PPIs | Conditional, very low |
| Methane | Suggests testing for methane in symptomatic patients with constipation | Conditional, very low |
| Treatment | Suggests antibiotics in symptomatic patients with SIBO to eradicate overgrowth and resolve symptoms | Conditional, low |
A few details are easy to miss.
The guideline does not grade the breath test itself. Because the clinical definition of SIBO is unclear without validated patient-reported outcomes, the use of breath testing is listed as a "key concept", not a graded recommendation. It also states that current breath tests have low sensitivity and specificity and that more validation is needed for standardization.
It sets a culture threshold, and notes the limits of culture. The guideline adopts a duodenal or jejunal aspirate count of at least 1,000 colony-forming units per milliliter (10³ CFU/mL) as the most suggestive of SIBO, noting that this is based on growth of culturable bacteria only.
It describes vitamin deficiency as not common. The guideline's key concepts state that vitamin deficiencies in SIBO are usually seen in people with an iatrogenic or structural abnormality such as a blind loop, and that folate may actually be elevated because bacteria produce it. That contradicts a lot of online content.
It declines to endorse several popular add-ons. There is "a lack of consistent data" to recommend specific probiotics, and "currently no basis" for fecal microbiota transplant in SIBO. Methane on a breath test, the guideline says, does not indicate SIBO at all, because methanogens are archaea, not bacteria, and it prefers the term intestinal methanogen overgrowth.
It puts causes first. Treatment of the underlying cause is described as the primary mode of prevention, to avoid repeated antibiotic courses.
Finally, the guideline carries a competing-interests statement like every guideline, and it is worth reading. Several authors disclosed grant support, advisory roles or equity in companies, including Salix Pharmaceuticals, which markets a rifaximin product. That does not make the guideline wrong. It is a reason that independent appraisals, like the 2024 one above, are useful, and the reverse applies to critics, whose disclosures you should also read.
For how this plays out when symptoms look like IBS, see our longer comparison in SIBO vs IBS symptoms.
What does the North American breath-testing consensus say?
The 2017 North American consensus concluded that glucose and lactulose breath tests remain the least invasive ways to diagnose SIBO, and defined a positive result as a hydrogen rise of at least 20 parts per million by 90 minutes. It also acknowledged that standardization of indications, preparation and interpretation had been lacking.
The expert meeting, preceded by a survey of 17 clinician-scientists and attended by 10, produced 28 statements in five areas: indications, preparation, performance, interpretation and knowledge gaps. Consensus was reached on 26. It recommended 75 g of glucose or 10 g of lactulose as the substrate, a methane level of at least 10 ppm as methane-positive, and a hydrogen rise of at least 20 ppm from baseline within 90 minutes as positive for overgrowth (Rezaie 2017).
That document is what many clinics follow when they interpret a result. It is also what critics argue against, specifically the 90 minute cut-off applied to lactulose. The 2024 appraisal points out that in the original validation work on lactulose transit, healthy volunteers had an average mouth-to-caecum time of 72 minutes with a range from 25 to 118 minutes, and that people with diarrhea-predominant IBS tend to have faster transit still. If the sugar reaches the colon within the window, the colon's own bacteria ferment it and the test reads positive, even with no overgrowth (Kashyap 2024). The Asian-Pacific and European guidance reportedly prefer glucose for this reason, and the ACG itself notes lactulose has been criticized for high false-positive values.
So the consensus is not wrong that the test is simple and safe. The disagreement is whether a number that is easy to measure is measuring the thing it claims to.
Why are SIBO breath tests contested?
Breath tests are contested because they measure gas, not bacteria in the small bowel, and the result depends on transit speed, the sugar used and the threshold chosen. Against the traditional reference, duodenal aspirate culture, the glucose breath test had 42% sensitivity and 84% specificity. But the reference is also imperfect.
Think of it as three linked problems.
1. Accuracy against the reference is modest. In a US study of 139 patients with unexplained gas, bloating and diarrhea and normal endoscopy, imaging and blood tests, duodenal culture was positive in 44.6% and the glucose breath test in 27.3%. Diagnostic agreement between the two was 65.5%. The glucose breath test had a sensitivity of 42%, specificity of 84%, positive predictive value of 68% and negative predictive value of 64% (Erdogan 2015). Those authors still concluded that, because the breath test is non-invasive, it is reasonable to try first.
2. The reference itself is not a gold standard. A systematic review of 71 papers found diagnostic studies to be very heterogeneous and concluded there is "no validated diagnostic test or gold standard for SIBO", noting that not even the culture studies met the quality standards for diagnostic research (Khoshini 2008). The aspirate cut-off has moved from 100,000 CFU/mL to 1,000 CFU/mL and the sampling site from jejunum to duodenum over time (Kashyap 2024). Culture also only detects bacteria that grow in a dish.
3. Positive results turn up in people without symptoms. In a pooled analysis of 25 case-control studies with 3,192 people with IBS and 3,320 controls, breath testing was positive in 35.5% of those with IBS and 29.7% of controls. Overgrowth was more common in IBS (odds ratio 3.7, 95% CI 2.3 to 6.0), but the authors rated the overall quality of evidence as low, citing inconsistent definitions and limited test accuracy (Shah 2020). The same review found lactulose testing positive far more often than glucose testing in both groups.
A further wrinkle comes from a Mayo Clinic study that went beyond culture. It found that SIBO defined by duodenal aspirate culture reflected an overgrowth of anaerobes, did not correspond with patient symptoms, and may be a result of dietary preferences, while the composition of the small intestinal microbiome was altered in symptomatic patients and did not track the culture result (Saffouri 2019). In plain terms, "how many bacteria" may be the wrong question and "which bacteria, doing what" may be the right one. That is not a rejection of the idea that small bowel microbes matter. It is a suggestion that the current definition is crude. Related: what foods do not trigger SIBO?
A good illustration is the treatment trial evidence. In the large phase III studies that led to FDA approval of rifaximin for non-constipated IBS, only 98 of 1,260 participants had a lactulose breath test. Among that small subset, breath tests normalized in 29%, and the post-treatment breath result did not predict who responded (Kashyap 2024). So the drug may help some people with IBS-type symptoms, but that does not prove the mechanism was clearing overgrowth.
Why are some gastroenterologists skeptical of SIBO?
Skeptical gastroenterologists mostly object to three things: that breath tests are being used to diagnose a condition they were not validated for, that a positive result does not predict who benefits from antibiotics, and that repeated broad-spectrum courses carry real costs. Few object to the classical disease with a clear anatomical cause.
Here is each objection in its strongest form, followed by what the other side says.
"The test was built for something else." The lactulose breath test was designed to measure transit time. Using it as an overgrowth test in IBS, critics argue, changed the definition of SIBO from a measurable clinical syndrome to "whatever the test says" (Kashyap 2024). Supporters reply that breath testing has been used and studied for decades, that standardized preparation reduces error, and that culture is invasive and not available everywhere.
"A positive result does not tell you who will improve." The 2024 appraisal notes that in the rifaximin phase III data, normalizing the breath test was not predictive of response. The AGA practice update makes a related point: IBS responds to a poorly absorbed antibiotic, but "the role of SIBO or its eradication in the genesis of this response warrants further confirmation in randomized controlled trials" (Quigley 2020). Supporters point out that rifaximin was approved by the FDA for non-constipated IBS on the strength of phase III trials, and that retesting after treatment can correlate with symptom improvement.
"Antibiotics are not free." The AGA update notes a "limited database to guide the clinician in developing antibiotic strategies for SIBO, in any context", that therapy "remains, for the most part, empiric", and that clinicians must be mindful of the potential risks of long-term broad-spectrum antibiotic therapy (Quigley 2020). When SIBO is tested for and treated repeatedly in people whose symptoms keep returning, the cumulative exposure is a legitimate worry.
"It is being diagnosed too easily." A non-systematic review published under the title "Is SIBO a real condition?" took a deliberately balanced line: it argued that testing and treating can give clinically significant relief, but that this must be done with circumspection to prevent over-testing, over-treatment and fear around certain foods (Ruscio 2019). Note that this is a non-systematic review, the weakest of the study designs cited here, so it is useful for framing the debate, not as strong evidence.
Notice the common thread. None of these objections says bacteria in the small bowel are irrelevant. They say that the current tools do not allow a confident, individual-level answer in common cases, and that the downstream treatment has been applied faster than the evidence has grown. A practitioner can hold that view and still take a patient's symptoms seriously, which is the thing many people on the forums, understandably, say they did not experience.
What are the established risk factors for SIBO?
The best-supported risk factors are anatomical or motility problems that let bacteria stagnate or travel upstream: abdominal surgery such as Roux-en-Y bypass, bowel resection and ileocolonic anastomosis, structural problems such as small bowel diverticulosis or fistulas, and diseases like systemic sclerosis that slow gut movement. Acid suppression is associated, but with weaker evidence.
The ACG explains the logic through the mechanisms that normally keep the small bowel's bacterial numbers low: gastric acid, pancreatic enzymes, bile acids, small bowel motility, the ileocaecal valve and the immune system. Anything that weakens one of those gatekeepers raises the plausible risk (Pimentel 2020). The table below shows how strong the human evidence is for each group.
| Risk factor | What the evidence shows | How much weight to give it |
|---|---|---|
| Abdominal surgery and altered anatomy (Roux-en-Y, ileocolonic anastomosis, post-radiation stricture, diverticulosis, fistula) | Listed in the ACG guideline as showing higher prevalence of SIBO. The classical blind-loop syndrome was described over a century ago | Strongest. Mechanism is clear and long recognized, though graded recommendations for testing remain "very low" evidence |
| Systemic sclerosis (scleroderma) | Pooled prevalence of 34% across 14 studies. Odds ratio 12.51 (95% CI 6.51 to 24.03) versus healthy controls. Higher with lactulose testing (56%) than glucose (27%) | Strong association, but numbers depend heavily on which test was used |
| Diabetes mellitus | Pooled prevalence 29% across 14 studies, but the odds ratio versus controls was 2.91 with a confidence interval of 0.82 to 10.32, which is not statistically significant | Suggestive, not established |
| Crohn's disease in remission | The ACG cites 16.8% with SIBO on breath testing in one study, associated with ongoing GI complaints | Limited, single-study data |
| Other motility conditions (Parkinson disease, hypothyroidism, chronic renal failure, amyloidosis) | The ACG states these are associated with SIBO but that multicenter randomized trials are lacking | Plausible, evidence limited |
| Acid suppression (PPIs) and loss of stomach acid (gastrectomy, autoimmune gastritis) | Hypochlorhydria and gastrectomy raise risk per the ACG. PPI association varies by study | Mixed, see next section |
| Older age, female sex | Associated with higher likelihood in the ACG review, possibly through slower transit | Weak, observational |
Two points from this table deserve emphasis. First, the numbers for systemic sclerosis and diabetes come from breath tests and aspirate cultures that are themselves imperfect, which is a good reason for caution about the exact percentages (Feng 2021; Feng 2022). Second, a risk factor is not a diagnosis. Having had abdominal surgery makes it more reasonable for a clinician to consider SIBO when you have new bloating and diarrhea afterwards; it does not make a symptomatic person automatically positive.
A frequent comment in the Reddit threads is that doctors only accept SIBO after abdominal surgery. That is the classic textbook picture, so it is not a bad starting point, but it is incomplete, and the ACG recognizes motility and acid-related contributors as well. Equally, the claim that "everyone with bloating has SIBO" is not supported.
Do PPIs cause SIBO? How good is the evidence?
Acid-suppressing proton pump inhibitors are associated with SIBO in some meta-analyzes, with odds roughly 1.7 times higher, but the evidence is observational and inconsistent. Other studies, particularly in people with IBS, found no association, and the ACG says dose and duration effects could not be determined.
The meta-analysis most often cited pooled 19 studies with 7,055 participants and found an odds ratio of 1.71 (95% CI 1.20 to 2.43) for SIBO among PPI users, with the association appearing in studies that used aspirate culture and glucose breath testing. The authors described the link as "moderately" increased and called for appropriate prescribing of PPIs (Su 2018). The ACG guideline reports additional data: in one study of 42 patients given eight weeks of a PPI, all with negative glucose breath tests beforehand, 26% were positive afterwards with more bloating, flatulence, pain and diarrhea (Pimentel 2020).
Now the caveats, which matter for anyone reading this while taking a PPI:
- Observational data. Most studies compare people who happen to take a PPI with people who do not. People are often prescribed PPIs because they already have upper GI symptoms, and some of those conditions affect motility or the microbiome in their own right.
- The IBS subgroup looks different. In the Shah analysis, PPI use was not associated with SIBO among patients with IBS (odds ratio 0.8, 95% CI 0.5 to 1.5) (Shah 2020). The 2024 appraisal notes that others have also found no association.
- Dose and duration remain unclear. The ACG notes that most studies did not find a relationship with duration, that some suggested double-dose therapy was more likely to be associated, and that a recent meta-analysis could not determine whether dose, duration or type mattered because of insufficient data.
- Test confounding. The 2024 appraisal argues that a positive glucose breath test may simply be a nonspecific marker of gastrointestinal disease, which would also make any "association" hard to interpret.
The practical message is modest. If you are on a PPI and have new or ongoing bloating, tell the doctor, because it is relevant history. Do not stop, change or reduce a prescribed acid suppressant on your own: it is prescribed for reasons, and the evidence here does not justify self-directed changes. The ACG itself suggests against routine breath testing in people on PPIs who have no symptoms.
How common is SIBO, and how does it relate to IBS?
Nobody knows how common SIBO is in the general population, because it depends on the definition and the test. In IBS, pooled analyzes found breath-test positivity in roughly a third of patients, but also in almost 30% of controls, and the evidence is rated low quality.
The AGA update says the true prevalence is "undefined" (Quigley 2020). In the Shah analysis, culture-based studies found a prevalence of 13.9% in IBS and 5.0% in controls at the stricter colony-count cut-off, and 33.5% versus 8.2% at the looser one. Lactulose breath testing produced much higher positive rates than glucose in both groups (Shah 2020). The ACG's own key concept is carefully worded: "a proportion of subjects with IBS are found to have SIBO", on both breath testing and culture.
In other words, the associations are real, the effect size varies enormously with the method, and a positive result in an individual is only weakly informative. If you want the practical detail on how to compare the two, our post on SIBO vs IBS symptoms covers the overlap, the other conditions with clearer tests (celiac disease, inflammatory bowel disease, bile acid malabsorption) and why symptoms cannot separate them.
What does SIBO treatment evidence actually show?
Antibiotics are the main treatment studied. A meta-analysis of 32 studies and 1,331 patients found rifaximin eradicated overgrowth on retesting in about 71% of cases, but rated study quality as generally poor. The ACG makes a conditional recommendation for antibiotics based on low-quality evidence. Recurrence is common.
The details matter if you are trying to judge how confident to be.
Treatments still being studied, such as fecal microbiota transplantation, are covered in can a fecal transplant cure SIBO.
- Efficacy is based on breath-test normalization, not just symptoms. The rifaximin meta-analysis found eradication in 70.8% by intention-to-treat and adverse events in 4.6%. Among the ten studies that reported symptom outcomes in people whose SIBO was eradicated, improvement or resolution was 67.7%, with a very wide confidence interval (44.7% to 86.9%). The authors concluded the drug "seems effective and safe" but that the quality of studies was generally poor and well-designed randomized trials are needed (Gatta 2017).
- Only one study compared rifaximin with placebo, according to the ACG's review, and treatment regimens varied widely in dose and duration (Pimentel 2020).
- Recurrence is frequent. In a follow-up of 80 adults whose SIBO was cleared with rifaximin, breath tests turned positive again in 12.6% at three months, 27.5% at six months and 43.7% at nine months (Lauritano 2008). The ACG points out that retreatment is common practice but is "solely based on anecdotal evidence and expert opinion".
- Diet, probiotics and other add-ons lack strong evidence. The ACG finds inconsistent data for specific probiotics and no basis for fecal transplant in SIBO. For food, see SIBO diet vs low FODMAP, which covers what has and has not been trialled.
- Addressing the cause is the stated priority. Both the ACG and AGA stress identifying and correcting underlying causes where possible, and correcting nutritional deficiencies (Quigley 2020).
This page does not recommend any antibiotic, herbal or other regimen, and the decision to take one belongs with a prescriber who knows your history. If you have been treated and feel worse in the days afterwards, we cover why in a separate guide: why you can feel worse after SIBO treatment.
If you are wary of antibiotics, our guide to whether SIBO can be treated without antibiotics grades the evidence for herbals, an elemental diet, probiotics, diet and prokinetics side by side.
Why was my SIBO diagnosis delayed for years?
Delays are common because the symptoms overlap with many conditions, the diagnosis is contested, and several of the standard tests (bloods, endoscopy, imaging) are often normal in SIBO. Reddit threads describe waits of a year or two, but individual stories are not a measure of how common this is.
A theme across the r/SIBO threads is that bloods and scans came back normal, which led clinicians to dismiss the problem or assign an IBS label, before a breath test finally flagged something. That pattern is plausible: SIBO and IBS share symptoms, and neither shows up on routine blood tests. But three cautions apply.
- A late positive breath test does not prove the delay was an error. Given the false-positive and false-negative rates described above, a positive result after a long search is information, not a verdict.
- Other treatable conditions can look the same. The AGA update notes that there is insufficient evidence to use inflammatory markers such as fecal calprotectin to detect SIBO, which is why calprotectin and other tests are done for inflammatory bowel disease instead. Celiac disease, bile acid malabsorption, lactose intolerance and pancreatic insufficiency are also on the usual list.
- Some delay is structural, not personal. If you have felt dismissed more broadly, see how to get your doctor to take IBS seriously for what drives that and what actually changes clinician behavior.
If testing is not available to you, can you treat SIBO without a breath test? explains when clinicians offer an empiric trial and the trade-offs.
What should I ask my doctor about SIBO?
Ask what exactly is being doubted, whether your history includes risk factors, which other causes should be excluded first, whether a breath test would change what you do, and what the plan is if the test is negative. Bring a short timeline of symptoms, surgeries, antibiotics and acid-suppressing medicines.
Here is a script you can adapt. It is built around the debate above, so that the conversation is about evidence and not about whether either of you "believes in" SIBO.
Opening. "I have had bloating and [diarrhea / constipation / pain] for [time]. I have read that SIBO is contested. Can you tell me what you think is going on, and what you would rule out first?"
Clarify the disagreement. "When you say SIBO is not a good explanation for me, do you mean the condition does not exist, that the breath test is unreliable, or that treating it would not help?" Those are three separate claims, and a good answer will tell you which one the clinician holds.
Raise your history. "I have had [abdominal surgery / a bowel resection / a gallbladder removal / long-term acid suppressants / repeated antibiotics / diabetes / a condition that slows the gut]. Does that change your thinking?" The ACG singles out previous luminal abdominal surgery and suspected motility disorders as the situations where testing is most clearly suggested.
Ask about alternatives. "What else should we exclude? Could this be celiac disease, inflammatory bowel disease, bile acid malabsorption or something dietary?" These have clearer tests and treatments.
Ask how the test would be used. "If I had a breath test, which substrate would you use, and what would you do with a positive or a negative result?" This reveals whether testing would change management or just add a label.
Ask about the plan and risks. "If antibiotics were an option, what would we be aiming to improve, how would we know it worked, and what happens if symptoms return?" The recurrence data above are a good reason to ask this up front.
Ask what would prompt a second opinion. If your concerns are dismissed without discussion, asking for a referral to a gastroenterologist with an interest in motility or functional disorders is reasonable. This is a normal request, not an insult.
For general preparation, our guides on preparing for a GI appointment and explaining IBS to a doctor cover what to bring and how to present it concisely.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
How should I track symptoms before raising SIBO with a doctor?
Keep a simple record for about four weeks: meals, bowel movements with Bristol stool form, bloating and pain ratings with times, and any antibiotic, acid-suppressant or surgery history. The purpose is not to diagnose SIBO but to give the clinician a clear pattern to reason from. If brain fog, poor sleep or anxiety are part of your picture, add them to the same record, as covered in can SIBO cause anxiety, insomnia and brain fog?
A tracking record helps in a way that matters for this specific debate, because the whole argument is about whether a test result explains symptoms. A clinician who can see that bloating peaks two hours after particular meals, or that diarrhea follows a course of antibiotics, or that the pattern changed after a surgery, can judge for themselves how much weight a breath test deserves. Without that, the test result tends to become the story.
What to record:
- Timing. When symptoms start relative to meals, and how long they last.
- Stool form and frequency, using the Bristol scale so that you and the doctor mean the same thing.
- Medicines and procedures. Dates of antibiotic courses, acid suppressants, opioids, abdominal surgery or bowel resection. Do not change any medicine to "test" a theory.
- Red flags. Blood in stool, weight loss, fever, night-time symptoms. These should prompt a call to your doctor, not a diary entry.
Pen and paper works fine, and our symptom tracker for doctor visits guide covers how to summarize a diary. If you would rather use an app, Clairop on iPhone logs meals, stools on the Bristol scale and symptom sliders; here is how it works. For a wider comparison of options, see our list of symptom tracker apps for GI appointments. No tracker can tell you whether you have SIBO.
What are the common myths about SIBO being "real" or "fake"?
The most common errors run in both directions: that SIBO is a pseudoscientific invention, and that SIBO explains nearly every digestive complaint. Both are overstated. The evidence supports a real condition with a contested boundary.
Myth: "SIBO was only discovered recently, so doctors were never taught it." The classical syndrome, usually called blind loop syndrome, was documented in the late nineteenth and early twentieth centuries (Kashyap 2024). What is recent is the broader application to IBS-type symptoms and the commercial rise of breath testing.
Myth: "A positive breath test proves SIBO." Breath tests are indirect. Roughly three in ten controls tested positive in the pooled analysis, and lactulose is especially prone to false positives from fast transit.
Myth: "A negative breath test proves you do not have it." Glucose is absorbed in the proximal small bowel, so it can miss distal overgrowth, and the glucose breath test had 42% sensitivity against culture in one study.
Myth: "SIBO is always the root cause of IBS." The ACG says a proportion of people with IBS are found to have SIBO. The AGA says the role in common functional symptoms remains controversial.
Myth: "Methane on a breath test is SIBO." The ACG says methane does not indicate SIBO because methanogens are archaea, and prefers the term intestinal methanogen overgrowth.
Myth: "SIBO always causes vitamin deficiency." The ACG says deficiencies are not common and are mostly seen with structural abnormalities. Folate can even be raised.
Myth: "Skeptical doctors are just uninformed or dismissive." Some are, and dismissal is a real problem. But the most prominent critiques come from authors who have published extensively on the topic, and their arguments are specific and checkable. Treating them as ignorance makes it harder to have a productive conversation.
Myth: "If doctors will not treat it, a non-medical route is the answer." Some people in the threads describe turning to naturopaths. Regulation, training and evidence vary widely by country and by practitioner, and several popular SIBO regimens have no randomized trial support. If you try an alternative practitioner, ask for the evidence behind any test or protocol they propose, and keep your regular doctor informed about anything you take.
When should I see a doctor promptly instead of chasing a SIBO diagnosis?
See a doctor promptly if you have blood in your stool or black stools, unintended weight loss, fever, symptoms that wake you at night, pale greasy stools, signs of anemia, symptoms starting after 50, a new and persistent change in bowel habit, or a family history of bowel cancer, celiac disease or inflammatory bowel disease.
These features point to conditions that have clearer tests and need investigation regardless of whether SIBO is involved. Debating breath-test validity while a red flag goes uninvestigated is the worst use of time. The same applies to persistent diarrhea with weight loss or fatty stools, which can reflect malabsorption of any cause, including the classical, anatomical form of overgrowth.
If you have none of those and your doctor has examined you and considered the usual alternatives, a disagreement about SIBO is a reasonable thing to resolve with a second opinion from a gastroenterologist, not something to settle alone.
The bottom line
SIBO is real, and so is the controversy. The condition has a long, well-documented history in people with surgery, strictures and severe motility disorders. The disputed territory is the larger one: whether small bowel bacteria explain ordinary bloating, whether the tests we have can tell, and whether repeated antibiotic courses are justified on that basis. The ACG guideline is honest about this, grading every recommendation as conditional on low-quality evidence, and its critics are honest about what they would replace it with: better measurement of the small intestinal microbiome, not denial that it matters.
For you, the useful move is to turn "is it real?" into three sharper questions: what is my risk, what would a test change, and what else needs ruling out. A doctor who engages with those has taken your symptoms seriously, whichever side of the debate they sit on.




